Trovagene Forms European Subsidiary Trovagene Research Institute

Trovagene, Inc.,

announced today the establishment of Trovagene Research Institute (TRI), a European subsidiary focused on expanding the capabilities and adoption of the Company's Precision Cancer Monitoring℠ (PCM) platform. Alberto Bardelli, Ph.D., an internationally recognized leader in cell-free DNA cancer research, will be the Scientific Chair of TRI. Dr. Bardelli, currently affiliated with the Department of Oncology, Torino Medical School and the Candiolo Cancer Institute in Italy, was among the first to identify mutations in the kinase genes associated with colorectal cancer and other malignancies while at Johns Hopkins University. He has authored or co-authored over 140 published papers, including his team's most recent widely acclaimed publication in Nature Medicine1, entitled Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. "Trovagene's vision for the broad applications of its liquid biopsy platform in the treatment of cancer patients and the Company's commitment to innovative cell-free DNA technologies were key factors in my decision